HomePress-release

Redding, California - June 13, 2024

Europe Single-use Bioreactors Market to be Worth $3.34 Billion by 2030

Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User - Forecast to 2030

Meticulous Research^®—a leading global market research company, published a research report titled ‘Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User – Forecast to 2030.’

According to this latest publication from Meticulous Research^®, the Europe single-use bioreactors market is projected to reach $3.34 billion by 2030, at a CAGR of 15.3%. Increasing adoption of disposable technologies in the pharmaceutical and biotechnology industries, capacity expansions of biopharmaceutical plants, increasing pharmaceutical R&D expenditures, the rising adoption of biosimilars, and the growing prevalence of chronic diseases owing to the aged population are the factors driving the growth of this market.

Europe Single-use Bioreactors Market: Future Outlook

The Europe single-use bioreactors market is segmented by Product {Single use Bioreactor Systems (Upto 10L, 11L-500L, 501L-1000L, and above 1001L), Media Bags (2D, 3D, and Linear), Filtration Assemblies, and Other Products}, Type (Stirred-Tank, Wave-Induced, and Other Types), Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, and Other Cell Types), Application [Commercial Bioproduction (mAb Production, Vaccine Production, Therapeutic Protein Production, and Cell and Gene Therapy) Research Bioproduction], End User {Pharmaceutical and Biopharmaceutical Companies; Contract Research Organizations and Contract Development and Manufacturing Organizations (CDMO); and Academic and Research Institutes}, and Geography. The study also evaluates industry competitors and analyzes their country-level market share.

Based on product, the Europe single-use bioreactor market is segmented into single-use bioreactor systems, media bags, filtration assemblies, and other products. In 2024, the single-use bioreactor systems segment is expected to account for the largest share of the market. The major reasons behind this share are their advantages. These advantages include lesser cleaning requirements, more flexibility, a smaller footprint, less capital investment, and reduced risk of cross-contamination. Moreover, vendors’ focus on large-scale bio-manufacturing supported the growth. Also, increasing demand by biopharma companies to reduce excess costs when using traditional instruments raises their adoption.

Among the type, in 2024, the stirred-tank bioreactors segment is expected to account for the largest share of the market. Increased use of stirred-tank bioreactors for CHO cell lines & suspension culture and large volume bio-production along with the latest design compared to traditional ones supported the share.

Among the cell type, in 2024, the mammalian cells segment is expected to account for the largest share of the market. Mammalian cells are considered a widely adopted experimental model, and hence their use for commercial & research bioproduction, like developing complex biomolecules such as monoclonal antibodies and therapeutic proteins and extensive use in clinical research for the majority of experiments supported the market share.

Among the application, in 2024, the commercial bio-production segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the rising production of biosimilars, an increasing number of genetic & rare diseases, and government support for the production of vaccines & immunization.

Among the end user, the contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) segment is projected to register the highest CAGR during the forecast period. The growth of this segment is driven by the outsourcing by the pharmaceutical and biopharmaceutical companies to CDMOs, key players’ preference for inorganic growth strategies, and expansion strategy by CDMOs. For instance, in July 2021, Viralgen VC (Spain) opened its new manufacturing facility in Basque, Italy. This facility is associated with adeno-associated virus gene therapy production.

Geographic Review

This research report analyzes major geographies and comprehensively analyzes European countries Germany, France, the U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, and the Rest of Europe. In 2024, Germany is expected to account for the largest share of the Europe single-use bioreactors market. The large share of this market is attributed to the increasing sales of drugs, support from government and regulatory authorities to promote the use of biopharmaceuticals for various health indications, and various companies expanding their manufacturing capacities as well as their operations.

Key Players

The key players profiled in the Europe single-use bioreactors market report are Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Solaris Biotechnology srl (Italy), Cellexus International Ltd. (U.K.) CESCO Bioengineering Co., Ltd. (Taiwan), PBS Biotech, Inc. (U.S.), Solida Biotech GmbH (Germany), and Infors AG (Switzerland).

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5552

Key questions answered in the report-

Which are the high-growth market segments in terms of type, cell type, application, end user, and country?
What was the historical market for single-use bioreactors across Europe?
What are the market forecasts and estimates for the period 2024–2030?
What are the major drivers, challenges, opportunities, and trends in single-use bioreactors in Europe?
Who are the major players in the Europe single-use bioreactors market?
What is the competitive landscape, and who are the market leaders in the Europe single-use bioreactors market?
What are the recent developments in the Europe single-use bioreactors market?
What are the different strategies adopted by the major players in the Europe single-use bioreactors market?
What are the geographical trends and high-growth countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - June 13, 2024

Europe Single-use Bioreactors Market to be Worth $3.34 Billion by 2030

Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User - Forecast to 2030

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies